|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash | |||||||||||
| Prepaid expenses | |||||||||||
| Deferred offering costs | |||||||||||
| Total current assets | |||||||||||
| Investments held in Trust Account | |||||||||||
| Total assets | |||||||||||
| Liabilities and shareholders’ deficit | |||||||||||
| Current liabilities: | |||||||||||
| Accrued expenses | |||||||||||
| Promissory note and working capital loan | |||||||||||
| Promissory Note | |||||||||||
| Working Capital Loan | |||||||||||
| Total promissory note and working capital loan | |||||||||||
| Due to related party | |||||||||||
| Promissory note and working capital loan | |||||||||||
| Promissory Note | |||||||||||
| Working Capital Loan | |||||||||||
| Total current liabilities | |||||||||||
| Warrant liabilities | |||||||||||
| Deferred underwriting commissions | |||||||||||
| Total liabilities | |||||||||||
| Class A ordinary shares, $0.0001 par value; 45,604,260 and 100,000,000 shares subject to possible redemption at $10.68 and $10.13 per share at September 30, 2023 and December 31, 2022, respectively | |||||||||||
| Shareholders’ deficit | |||||||||||
| Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding | |||||||||||
| Common stock | |||||||||||
| Class A Ordinary Shares included as part of the units | |||||||||||
| Class B Ordinary Shares | |||||||||||
| Additional paid-in capital | |||||||||||
| Accumulated deficit | |||||||||||
| Class A Ordinary Shares Subject To Redemotion | |||||||||||
| Total shareholders’ deficit | |||||||||||
| Total liabilities and shareholders’ deficit |
Loading...
